Real-World Assessment of Ritlecitinib in Patients with Severe Alopecia Areata: A 24-Week Multicentre Retrospective Study

    July 2025 in “ Clinical and Experimental Dermatology ”
    Luca Valtellini, Gianluca Avallone, Giulia Murgia, Gabriele Perego, Isotta Giunipero di Corteranzo, Carlo Alberto Vignoli, Luigi Gargiulo, Simone Ribero, Pietro Quaglino, Giuseppe Gallo, Antonio Costanzo, Alessandra Narcisi, Mauro Barbareschi, Angelo Valerio Marzano, Silvia Mariel Ferrucci
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Studysummary This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial. Our plain-language summary of this paper — not a Tressless recommendation.
    This 24-week multicentre retrospective study assessed the real-world effectiveness and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with severe alopecia areata (AA) across three Italian tertiary referral centres. The study found that ritlecitinib demonstrated a higher rate of Severity of Alopecia Tool score 20 responses compared to the ALLEGRO trial, indicating improved treatment outcomes in a real-life setting. This suggests that ritlecitinib may be a more effective therapeutic option for AA than conventional treatments, addressing the need for better management of this chronic autoimmune disorder.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results